Espec has revised its capital cost to 10% and set its ROE target for the mid-term management plan at over 12.0%. Although the ROE for FY2025 was 10.0% and did not meet the target, the stock price is considered undervalued.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"6859","jir_company_name":"Espec Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-05-14","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/6859-20260514-01.pdf","jir_short_summary":"Espec has revised its capital cost to 10% and set its ROE target for the mid-term management plan at over 12.0%. Although the ROE for FY2025 was 10.0% and did not meet the target, the stock price is considered undervalued.","jir_summary":"### Performance Overview\nEspec revised its capital cost from the conventional 8% to 10% at the Board of Directors meeting in May 2026, setting its ROE target at over 12.0%. Although the ROE for FY2025 was 10.0%, failing to meet the target, net sales increased to 70,034 million yen, up 4.2% from the previous year. Net income was 5,879 million yen, showing a slight decline. The stock price remains undervalued, and the company is advancing its mid- to long-term growth strategy and strengthening IR activities.\n\n### Future Outlook and Strategies\nEspec has revised its mid-term management plan 'PROGRESSIVE PLUS 2027,' aiming for net sales of 76 billion yen, operating profit of 9.1 billion yen, and ROE of over 12.0% in FY2027. While emphasizing capital efficiency, the company is proactively promoting growth investments and shareholder returns, maintaining a healthy financial position with a debt-to-equity ratio controlled within 70%. Furthermore, it is focusing on expanding revenue through areas such as AI semiconductors, autonomous driving, and satellite communications, while also strengthening IR activities.","jir_financial_highlights":"ROE (%): 10.0 (No change compared to FY2024)\nNet Sales (million yen): 70,034 (+4.2% compared to FY2025)\nNet Income (million yen): 5,879 (-1.2% compared to FY2025)","jir_category":"","jir_hashtags":"#Espec, #IR, #JapanStocks","jir_key_figures":"Net Sales: 70,034 million yen (FY2026)\nROE: 10.0% (FY2025)\nCapital Cost: Revised to 10%","jir_meta_title":"\u3010Espec\u3011Revision of Capital Cost and Mid-term Plan\uff5cMay 2026","jir_meta_description":"Espec has revised its capital cost to 10% and set its ROE target at over 12.0%. Although FY2025 ROE was 10.0% and did not meet the target, it is strengthening growth strategies and IR activities.","jir_og_title":"\u3010Espec\u3011Revision of Capital Cost and Mid-term Plan\uff5cMay 2026","jir_og_description":"Espec has revised its capital cost and set its ROE target to over 12%. Focused on growth strategies and IR activity enhancement.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16866,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-50334","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n